GT
CDLX icon

Glenmede Trust’s Cardlytics CDLX Stock Holding History

Glenmede Trust’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1
Closed – – 1388
2020
Q3 		$0 Buy
+1
New +$727 ﹤0.01% 2473

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Glenmede Trust's CDLX Position: Q4 2020 in Review

Glenmede Trust sold out of Cardlytics (CDLX) in Q4 2020, closing a stake of 1 share.

Glenmede Trust first reported a position in CDLX in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 195 funds tracked by Wall St. Rank hold CDLX as of Q4 2020.

  • Glenmede Trust reported no remaining Cardlytics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 1 Cardlytics share in Q4 2020.
  • Glenmede Trust first reported a position in Cardlytics in Q3 2020 and held it in 1 quarter.
  • Glenmede Trust's Cardlytics position peaked at $0 in Q3 2020.
  • 195 funds tracked by Wall St. Rank held Cardlytics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.